A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer

Recruiting now

Conditions studied: Thyroid Cancer, Thyroid, Refractory Thyroid Cancer

In brief

The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid cancer. This study is a registry study.

Key facts

Study ID
NCT05733013
Run by
Memorial Sloan Kettering Cancer Center
People needed
100
Starts
2023-02-07
Expected to finish
2028-02-07
Last updated by the study team
2026-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.